search

Active clinical trials for "Arthritis, Psoriatic"

Results 181-190 of 469

A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis With and...

ArthritisPsoriatic

The purpose of this study is to evaluate the efficacy (improvement of signs and symptoms) and safety of ustekinumab in patients with psoriatic arthritis.

Completed9 enrollment criteria

TIght COntrol of Psoriatic Arthritis

Psoriatic Arthritis

The purpose of this study is to investigate whether tight control of patients with newly diagnosed psoriatic arthritis (consisting of regular 4 weekly objective assessment of disease activity and protocol-led intensive treatment) can improve outcome as opposed to standard care (usually 3 monthly reviews with no objective outcome measures and no protocol for treatment). The principle hypothesis of this study is that tight control of inflammation in psoriatic arthritis using a treatment protocol and pre-defined objective targets for treatment will lead to an improvement in patients' disease activity and a reduction in radiological joint damage.

Completed16 enrollment criteria

Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severely Active Psoriatic...

ArthritisPsoriatic

Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects with Moderate to Severely Active Psoriatic Arthritis Subjects with Inadequate Response to Disease Modifying anti-Rheumatic Drug Therapy

Completed7 enrollment criteria

Study of the Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects...

ArthritisPsoriatic

Multicenter Study of the Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects with Moderately to Severely Active Psoriatic Arthritis

Completed7 enrollment criteria

Study of Intra-articular Delivery of tgAAC94 in Inflammatory Arthritis Subjects

ArthritisRheumatoid3 more

The 13G01 clinical trial is a Phase I/II dose escalation study designed to be conducted in adults with inflammatory arthritis who have persistent moderate or severe swelling in one or more joints, without a disease severe enough to warrant a change in regimen for the next three months. The study will permit subjects who are concurrently on anti-tumor necrosis factor (TNF)-alpha antagonists. For subjects on disease modifying antirheumatic drugs (DMARDs), a stable regimen for inflammatory arthritis for the previous three months, with no changes in doses in the four weeks prior to screening will be required. The primary objectives are: to evaluate the safety of intra-articular administration of tgAAC94 in subjects currently taking TNF-alpha antagonists, and to evaluate the safety of repeat intra-articular administration of tgAAC94 (gene therapy vector).

Completed20 enrollment criteria

An Effectiveness and Safety Study of CNTO 1275 in Patients With Active Psoriatic Arthritis

Psoriatic Arthritis

The purpose of this study is to evaluate the effectiveness and safety of CNTO 1275 (ustekinumab) in patients with psoriatic arthritis.

Completed13 enrollment criteria

Korea Xeljanz Post-marketing Surveillance for Juvenile Idiopathic Arthritis

Psoriatic ArthritisJuvenile1 more

This study is to assess the safety and effectiveness of Xeljanz in Juvenile Idiopathic Arthritis (JIA) patients in routine clinical practice in Korea. JIA patients experience persistent joint pain, swelling and stiffness. This is a prospective observational study. Xeljanz is a JAK inhibitor. It was first approved in 2014 for rheumatoid arthritis patients in Korea. The ministry of Food and Drug Safety in Korea mandates for a drug manufacturer to report the post-marketing surveillance after drug's approval or indication extension. This study is to see the safety and effectiveness of Xeljanz in Juvenile Idiopathic Arthritis patients in routine clinical practice in Korea. This study is seeking patients who: Are 2 to less than 18 years of age; Are given Xeljanz for the treatment of JIA. The study sponsor will monitor patients' treatment experience for up to 44 weeks. This will help assess the safety and effects of this study medicine.

Not yet recruiting8 enrollment criteria

Monocyte Chemoattractant Protein-1 in Psoriatic Arthritis Patients

Psoriatic Arthritis

Evaluate serum levels of (MCP-1) in PsA with or without cardiovascular affaction . Detect subclinical cardiovascular affaction in patients with PsA for early diagnosis and management .

Not yet recruiting10 enrollment criteria

A Study on Pharmacokinetics and Safety of BAT2506 Injection Versus Simponi®

Psoriatic Arthritis

This is a randomized, double-blind, parallel three-arm, and single-dose Phase I clinical study, designed to compare the similarity of pharmacokinetics, safety and immunogenicity between BAT2506 Injection and Simponi® (EU-licensed and US-licensed) after single subcutaneous administration in healthy Chinese male subjects.

Completed28 enrollment criteria

A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis

Psoriatic Arthritis

The main purpose of this study is to evaluate how effective and safe the study drug known as ixekizumab is in participants with active psoriatic arthritis.

Completed15 enrollment criteria
1...181920...47

Need Help? Contact our team!


We'll reach out to this number within 24 hrs